Related Experiment Video
Updated: Jun 5, 2026
10:16
In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Gaucher disease: clinical profile and therapeutic developments
1Department of Medicine, University of Cambridge, Cambridge, UK.
Biologics : Targets & Therapy
|January 7, 2011
Summary
Gaucher disease, a rare metabolic disorder, is treated with enzyme replacement therapy and emerging oral drugs. Gene therapy and other advanced methods offer future treatment possibilities for this orphan disease.
Area of Science:
- Biochemistry and Genetics
- Rare Diseases and Orphan Drugs
- Pharmacology and Therapeutics
Background:
- Gaucher disease is a rare inherited metabolic disorder caused by a deficiency in lysosomal acid β-glucocerebrosidase.
- This deficiency leads to the accumulation of glycosphingolipids, primarily in macrophages.
- The disease has been a significant model for the development of orphan drugs.
Purpose of the Study:
- To review the therapeutic landscape for Gaucher disease, encompassing enzyme replacement therapy, small molecule inhibitors, and emerging gene therapies.
- To highlight the evolution of treatment strategies from early methods like bone marrow transplantation to modern biotechnological approaches.
- To discuss the commercial and scientific impact of orphan drug development in the context of Gaucher disease.
Main Methods:
- Review of enzyme replacement therapy (ERT) using recombinant human β-glucocerebrosidase (imiglucerase) and its biosimilars (velaglucerase-alfa, taliglucerase-alfa).
- Analysis of small molecule inhibitors targeting glucosylceramide biosynthesis.
- Exploration of advanced therapeutic strategies including gene therapy for hematopoietic stem cells and direct brain delivery.
Main Results:
- Enzyme replacement therapy (ERT) has become a blockbuster treatment, significantly ameliorating key clinical manifestations.
- Biosimilar enzyme therapies and oral small molecule inhibitors offer competitive and alternative treatment options.
- While ERT is effective, certain aspects like skeletal and neurological involvement remain challenging, necessitating further research.
Conclusions:
- The therapeutic repertoire for Gaucher disease has expanded significantly, driven by orphan drug legislation and biotechnological innovation.
- Despite advances, unmet needs persist, particularly for skeletal and neurological complications, requiring continued scientific investment.
- Future research should focus on gene therapy and other innovative approaches to address the remaining challenges in Gaucher disease management.
Related Concept Videos
01:29Gastroesophageal Reflux Disease II: Clinical Features and Management
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
01:23Gastritis III: Clinical Manifestations and Management
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:29Chronic Pancreatitis II: Collaborative Care
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment: